T. Rowe Price Associates’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,415,865
| Closed | -$74.3M | – | 2776 |
|
|
2020
Q3 | $74.3M | Sell |
1,415,865
-4,961,656
| -78% | -$205M | 0.01% | 744 |
|
|
2020
Q2 | $212M | Buy |
6,377,521
+454,776
| +8% | +$14.5M | 0.03% | 456 |
|
|
2020
Q1 | $161M | Buy |
5,922,745
+51,560
| +0.9% | +$1.44M | 0.03% | 464 |
|
|
2019
Q4 | $116M | Buy |
5,871,185
+621,828
| +12% | +$9.94M | 0.02% | 618 |
|
|
2019
Q3 | $68M | Sell |
5,249,357
-128,783
| -2% | -$1.55M | 0.01% | 750 |
|
|
2019
Q2 | $67M | Sell |
5,378,140
-309,422
| -5% | -$4.11M | 0.01% | 775 |
|
|
2019
Q1 | $82.6M | Buy |
5,687,562
+57,982
| +1% | +$741K | 0.01% | 695 |
|
|
2018
Q4 | $62.2M | Buy |
5,629,580
+2,617,606
| +87% | +$36.4M | 0.01% | 740 |
|
|
2018
Q3 | $79.2M | Buy |
3,011,974
+2,192,784
| +268% | +$59.3M | 0.01% | 746 |
|
|
2018
Q2 | $16.8M | Buy |
819,190
+10,192
| +1% | +$219K | ﹤0.01% | 1254 |
|
|
2018
Q1 | $14.7M | Sell |
808,998
-387,048
| -32% | -$6.45M | ﹤0.01% | 1270 |
|
|
2017
Q4 | $16.7M | Buy |
1,196,046
+391,760
| +49% | +$5.3M | ﹤0.01% | 1243 |
|
|
2017
Q3 | $14.9M | Sell |
804,286
-2,800
| -0.3% | -$46.8K | ﹤0.01% | 1268 |
|
|
2017
Q2 | $13.6M | Sell |
807,086
-77,482
| -9% | -$1.18M | ﹤0.01% | 1262 |
|
|
2017
Q1 | $11.8M | Sell |
884,568
-126,156
| -12% | -$1.98M | ﹤0.01% | 1300 |
|
|
2016
Q4 | $15.2M | Buy |
1,010,724
+60,560
| +6% | +$800K | ﹤0.01% | 1221 |
|
|
2016
Q3 | $11.1M | Sell |
950,164
-1,700
| -0.2% | -$20K | ﹤0.01% | 1292 |
|
|
2016
Q2 | $10.3M | Sell |
951,864
-56,700
| -6% | -$585K | ﹤0.01% | 1287 |
|
|
2016
Q1 | $9.32M | Sell |
1,008,564
-258,055
| -20% | -$2.78M | ﹤0.01% | 1288 |
|
|
2015
Q4 | $18.8M | Sell |
1,266,619
-57,420
| -4% | -$961K | ﹤0.01% | 1102 |
|
|
2015
Q3 | $21.7M | Sell |
1,324,039
-2,659,675
| -67% | -$54.4M | ﹤0.01% | 1054 |
|
|
2015
Q2 | $90.9M | Sell |
3,983,714
-433,972
| -10% | -$8.64M | 0.02% | 628 |
|
|
2015
Q1 | $67.1M | Buy |
4,417,686
+1,829,074
| +71% | +$23.8M | 0.01% | 740 |
|
|
2014
Q4 | $31.2M | Sell |
2,588,612
-17,800
| -0.7% | -$203K | 0.01% | 996 |
|
|
2014
Q3 | $29.6M | Sell |
2,606,412
-11,900
| -0.5% | -$136K | 0.01% | 1007 |
|
|
2014
Q2 | $31.6M | Sell |
2,618,312
-660,927
| -20% | -$7.81M | 0.01% | 995 |
|
|
2014
Q1 | $38.2M | Sell |
3,279,239
-417,436
| -11% | -$7.07M | 0.01% | 932 |
|
|
2013
Q4 | $65.4M | Sell |
3,696,675
-2,600
| -0.1% | -$43.7K | 0.02% | 738 |
|
|
2013
Q3 | $53.2M | Sell |
3,699,275
-45,000
| -1% | -$689K | 0.01% | 796 |
|
|
2013
Q2 | $56.4M | Buy |
+3,744,275
| New | +$49.4M | 0.02% | 753 |
|
T. Rowe Price Associates's MNTA Position: Q4 2020 in Review
T. Rowe Price Associates sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,415,865 shares — an estimated $74.3M sold.
T. Rowe Price Associates first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $212M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- T. Rowe Price Associates reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 1,415,865 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $74.3M.
- T. Rowe Price Associates first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- T. Rowe Price Associates's Momenta Pharmaceuticals, Inc. position peaked at $212M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.